Effect of Interferon alfa-2a Treatment on Adaptive and Innate Immune Systems in Patients With Behcet Disease Uveitis

被引:32
|
作者
Albayrak, Ozgur [1 ]
Oray, Merih [2 ]
Can, Fusun [1 ]
Kirimli, Gunay Uludag [3 ]
Gul, Ahmet [4 ]
Tugal-Tutkun, Ilknur [2 ]
Onal, Sumru [5 ]
机构
[1] Koc Univ, Sch Med, Dept Med Microbiol, Istanbul, Turkey
[2] Istanbul Univ, Dept Ophthalmol, Istanbul Fac Med, Istanbul, Turkey
[3] Koc Univ Hosp, Dept Ophthalmol, Istanbul, Turkey
[4] Istanbul Univ, Div Rheumatol, Dept Internal Med, Istanbul Fac Med, Istanbul, Turkey
[5] Koc Univ, Sch Med, Dept Ophthalmol, Davutpasa Cad 4, TR-34010 Istanbul, Turkey
关键词
interferons; Behcet disease; uveitis; adaptive; innate; REGULATORY T-CELLS; TOLL-LIKE RECEPTORS; FLUORESCEIN ANGIOGRAPHY; EXPRESSION; POSTERIOR; TH17; STANDARDIZATION; RECOMMENDATIONS; IMBALANCE; RESPONSES;
D O I
10.1167/iovs.18-25548
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
PURPOSE. To investigate the effect of interferon alfa-2a on T regulatory (Treg) cells, T helper 17 (Th17) cells, and expression of Toll-like receptors (TLRs) in Behcet disease (BD) patients with uveitis. METHODS. Twenty-seven patients who received interferon alfa-2a for active BD uveitis despite conventional immunomodulatory therapies and healthy controls were enrolled. Peripheral blood Treg and Th17 cell frequencies were determined by flow cytometry as gated cells for CD3(+)CD4(+)Foxp3(+) and CD3(+)CD4(+)IL17A(+), respectively. Th17 RAR-related orphan receptor (ROR)gamma t mRNA expression was verified by real-time PCR (RT-PCR). Treg and Th17 cell cytokines were detected by ELISA in the supernatant of short-term cell cultures. RT-PCR was used to assess expression of TLR-2, TLR-3, TLR-4, TLR-8, and TLR-9 using cDNA prepared from CD4(+)T cells and monocytes. RESULTS. Treg and Th17 cell frequencies and Th17 ROR gamma t expression were significantly elevated, and IL-10 concentration in Treg cell supernatants was significantly lower in BD patients than in controls. Th17 IL-17, IL-6, IL-21, IL-22, IL-23, IFN-gamma, and TNF-alpha concentrations were significantly higher and all TLR expressions were significantly elevated in patients. Interferon alfa-2a led to a significant reversal in Treg and Th17 cell frequencies, Th17 ROR gamma t expression, Treg and Th17 cell cytokine production, and TLR expression by CD4(+)T cells and monocytes. CONCLUSIONS. Despite a relative increase in Treg cells, impaired IL-10 production suggests that Treg dysfunction may play a role in induction of BD uveitis. Favorable effects of interferon alfa-2a may be associated with recovery of Treg cell function, suppression of Th17 cells, and reduced expression of TLRs on CD4(+)T cells and monocytes.
引用
收藏
页码:52 / 63
页数:12
相关论文
共 50 条
  • [31] TREATMENT OF CHILDHOOD ANGIOMATOUS DISEASES WITH RECOMBINANT INTERFERON ALFA-2A
    WHITE, CW
    WOLF, SJ
    KORONES, DN
    SONDHEIMER, HM
    TOSI, MF
    YU, A
    JOURNAL OF PEDIATRICS, 1991, 118 (01): : 59 - 66
  • [32] TREATMENT OF MULTIPLE-MYELOMA WITH RECOMBINANT INTERFERON ALFA-2A
    OHNO, R
    KIMURA, K
    CANCER, 1986, 57 (08) : 1685 - 1688
  • [33] LYMPHOMATOID PAPULOSIS - TREATMENT WITH RECOMBINANT INTERFERON ALFA-2A AND ETRETINATE
    WYSS, M
    DUMMER, R
    DOMMANN, SN
    JOLLERJEMELKA, HI
    DOURSZIMMERMANN, MT
    GILLIET, F
    BURG, G
    DERMATOLOGY, 1995, 190 (04) : 288 - 291
  • [34] Long-term Efficacy and Safety of Low-Dose and Dose-Escalating Interferon Alfa-2a Therapy in Refractory Behcet Uveitis
    Onal, Sumru
    Kazokoglu, Haluk
    Koc, Aylin
    Akman, Mehmet
    Bavbek, Tayfun
    Direskeneli, Haner
    Yavuz, Sule
    ARCHIVES OF OPHTHALMOLOGY, 2011, 129 (03) : 288 - 294
  • [35] MANAGEMENT OF CANCER-PATIENTS RECEIVING INTERFERON ALFA-2A
    GAUCI, L
    INTERNATIONAL JOURNAL OF CANCER, 1987, : 21 - 30
  • [36] Interferon alfa-2a: A new treatment option for long lasting refractory cystoid macular edema in uveitis? A pilot study
    Deuter, Christoph M. E.
    Koetter, Ina
    Guenaydin, Ilhan
    Stuebiger, Nicole
    Zierhut, Manfred
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2006, 26 (07): : 786 - 791
  • [37] CELLULAR IMMUNE RESPONSES IN BEHCET'S DISEASE PATIENTS WITH UVEITIS DURING INFLIXIMAB TREATMENT
    Takeuchi, M.
    Karasawa, Y.
    Harimoto, K.
    Sakurai, Y.
    Sato, T.
    Caspi, R.
    Ito, M.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2016, 34 (06) : S144 - S144
  • [38] TREATMENT OF CUTANEOUS T-CELL LYMPHOMAS WITH INTERFERON ALFA-2A
    UNAL, A
    KARAOGLU, S
    SOYUER, U
    KONTAS, O
    ASCIOGLU, O
    EXPERIMENTAL HEMATOLOGY, 1993, 21 (08) : 1124 - 1124
  • [39] INTERFERON ALFA-2A IN THE TREATMENT OF CUTANEOUS T-CELL LYMPHOMA
    OLSEN, EA
    DIAB, NG
    CLINICAL RESEARCH, 1986, 34 (02): : A772 - A772
  • [40] Spastic diplegia as a complication of interferon Alfa-2a treatment of hemangiomas of infancy
    Barlow, CF
    Priebe, CJ
    Mulliken, JB
    Barnes, PD
    Mac Donald, D
    Folkman, J
    Ezekowitz, RAB
    JOURNAL OF PEDIATRICS, 1998, 132 (03): : 527 - 530